Product Portfolio Growth MedReleaf Australia expanded its cannabis product portfolio in 2024, introducing premium dried cannabis flower products and pastilles with 5 mg THC and 10 mg CBD. This demonstrates growing demand for diverse medical cannabis formats in Australia and New Zealand. Sales teams should equip GPs and pharmacists with updated product literature dosing guidance and samples to accelerate adoption.

Channel and Education As an asset light supplier focused on GPs and pharmacists across Australia and New Zealand, MedReleaf Australia offers a lean channel for scalable partnerships with pharmacies and clinics. The product launches create opportunities to co develop education programs and formulary placements with prescribers. A targeted channel strategy can speed product adoption in both markets.

Sustainability Focus MedReleaf Australia's partnership with CleanHub to offset plastic waste signals a strong sustainability story that resonates with procurement teams. There is room to co market eco friendly packaging and waste reduction programs to healthcare buyers. Aligning this messaging can differentiate offerings when engaging hospitals clinics and group purchasing organizations.

Regulatory Pathways Recent entries funded under the MedReleaf Concession Scheme indicate a regulatory pathway for higher THC products for qualified patients. The sales plan can emphasize compliance support physician training and patient education to lower access barriers. Messaging that aligns with MCS requirements can improve go to market effectiveness.

Aurora Advantage Being a wholly owned subsidiary of Aurora provides access to global cannabis expertise research and development capabilities and cross regional portfolio opportunities. This backing can accelerate market penetration in Australia and New Zealand and unlock premium product placements with large buyers. Aligning local territorial plans with Auroras network can expand account reach and growth opportunities.